Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study

Antonio Tursi, Giovanni Brandimarte, Alfredo Papa, Andrea Giglio, Walter Elisei, Gian Marco Giorgetti, Giacomo Forti, Sergio Morini, Cesare Hassan, Maria Antonietta Pistoia, Maria Ester Modeo, Stefano Rodino', Teresa D'Amico, Ladislava Sebkova, Natale Sacca', Emilio Di Giulio, Francesco Luzza, Maria Imeneo, Tiziana Larussa, Salvatore Di Rosa, Vito Annese, Silvio Danese, Antonio Gasbarrini, Antonio Tursi, Giovanni Brandimarte, Alfredo Papa, Andrea Giglio, Walter Elisei, Gian Marco Giorgetti, Giacomo Forti, Sergio Morini, Cesare Hassan, Maria Antonietta Pistoia, Maria Ester Modeo, Stefano Rodino', Teresa D'Amico, Ladislava Sebkova, Natale Sacca', Emilio Di Giulio, Francesco Luzza, Maria Imeneo, Tiziana Larussa, Salvatore Di Rosa, Vito Annese, Silvio Danese, Antonio Gasbarrini

Abstract

Objectives: VSL#3 is a high-potency probiotic mixture that has been used successfully in the treatment of pouchitis. The primary end point of the study was to assess the effects of supplementation with VSL#3 in patients affected by relapsing ulcerative colitis (UC) who are already under treatment with 5-aminosalicylic acid (ASA) and/or immunosuppressants at stable doses.

Methods: A total of 144 consecutive patients were randomly treated for 8 weeks with VSL#3 at a dose of 3,600 billion CFU/day (71 patients) or with placebo (73 patients).

Results: In all, 65 patients in the VSL#3 group and 66 patients in the placebo group completed the study. The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63.1 vs. 40.8; per protocol (PP) P=0.010, confidence interval (CI)₉₅(%) 0.51-0.74; intention to treat (ITT) P=0.031, CI₉₅(%) 0.47-0.69). Significant results with VSL#3 were recorded in an improvement of three points or more in the UCDAI score (60.5% vs. 41.4%; PP P=0.017, CI₉₅(%) 0.51-0.74; ITT P=0.046, CI₉₅(%) 0.47-0.69) and in rectal bleeding (PP P=0.014, CI₉₅(%) 0.46-0.70; ITT P=0.036, CI₉₅(%) 0.41-0.65), whereas stool frequency (PP P=0.202, CI₉₅(%) 0.39-0.63; ITT P=0.229, CI₉₅(%) 0.35-0.57), physician's rate of disease activity (PP P=0.088, CI₉₅(%) 0.34-0.58; ITT P=0.168, CI₉₅(%) 0.31-0.53), and endoscopic scores (PP P=0.086, CI₉₅(%) 0.74-0.92; ITT P=0.366, CI₉₅(%) 0.66-0.86) did not show statistical differences. Remission was higher in the VSL#3 group than in the placebo group (47.7% vs. 32.4%; PP P=0.069, CI₉₅(%) 0.36-0.60; ITT P=0.132, CI₉₅(%) 0.33-0.56). Eight patients on VSL#3 (11.2%) and nine patients on placebo (12.3%) reported mild side effects.

Conclusions: VSL#3 supplementation is safe and able to reduce UCDAI scores in patients affected by relapsing mild-to-moderate UC who are under treatment with 5-ASA and/or immunosuppressants. Moreover, VSL#3 improves rectal bleeding and seems to reinduce remission in relapsing UC patients after 8 weeks of treatment, although these parameters do not reach statistical significance.

Figures

Figure 1
Figure 1
Patient disposition.
Figure 2
Figure 2
Percentage of patients with reduction of ulcerative colitis disease activity index (UCDAI) > 50% or of at least three points, and patients in remission at week 8 (on intention-to-treat analysis). n.s., not significant.
Figure 3
Figure 3
Percentage of patients with improvement in different subgroups of ulcerative colitis disease activity index (UCDAI; rectal bleeding, stool frequency, physician rating of disease activity, and endoscopic score) at week 8 (on intention-to-treat analysis). n.s., not significant.

References

    1. Schwartz M, Cohen R. Optimizing conventional therapy for inflammatory bowel disease. Curr Gastroenterol Rep. 2008;10:585–590.
    1. Travis S, Stange EF, Lémann M, et al. For the European Crohn's and Colitis Organisation (ECCO). European evidence-based consensus of the management of ulcerative colitis: current management. J Crohn Colitis. 2008;2:24–62.
    1. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305–309.
    1. Gionchetti P, Rizzello F, Helwig U, et al. Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology. 2003;124:1202–1209.
    1. Tursi A, Brandimarte G, Giorgetti GM, et al. Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. Med Sci Monit. 2004;10:PI126–PI131.
    1. Bibiloni R, Fedorak RN, Tannock GW, et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol. 2005;100:1539–1546.
    1. Mallon P, McKay D, Kirk S, et al. Probiotics for induction of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;17:CD005573.
    1. Moser G. How often do patients with IBD have symptom recurrence. Inflamm Bowel Dis. 2008;14 (Suppl 2:S47.
    1. Rizzello F, Gionchetti P, D′Arienzo A, et al. Oral beclometasone dipropionate in the treatment of active ulcerative colitis: a double-blind placebo-controlled study. Aliment Pharmacol Ther. 2002;16:1109–1116.
    1. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2004;99:1371–1385.
    1. Pardi DS, D'Haens G, Shen B, et al. Clinical guidelines for the management of pouchitis. Inflamm Bowel Dis. 2009;15:1424–1431.
    1. Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol. 2009;296:G1140–G1149.
    1. Reiff C, Delday M, Rucklidge G, et al. Balancing inflammatory, lipid, and xenobiotic signaling pathways by VSL#3, a biotherapeutic agent, in the treatment of inflammatory bowel disease. Inflamm Bowel Dis. 2009;15:1721–1736.
    1. Kruis W, Schütz E, Fric P, et al. Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997;11:853–858.
    1. Rembacken BJ, Snelling AM, Hawkey PM, et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 1999;354:635–639.
    1. Kruis W, Fric P, Pokrotnieks J, et al. Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine. Gut. 2004;53:1617–1623.
    1. Guslandi M, Giollo P, Testoni PA. A pilot trial of Saccharomyces boulardii in ulcerative colitis. Eur J Gastroenterol Hepatol. 2003;15:697–698.
    1. Riquelme AJ, Calvo MA, Guzmán AM, et al. Saccharomyces cerevisiae fungemia after Saccharomyces boulardii treatment in immunocompromised patients. J Clin Gastroenterol. 2003;36:41–43.
    1. Famularo G, Trinchieri V, De Simone C. Inflammatory bowel disease. N Engl J Med. 2002;347:1982–1984.
    1. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther. 1999;13:1103–1108.
    1. Huynh HQ, deBruyn J, Guan L, et al. Probiotic preparation VSL#3 induces remission in children with mild to moderate acute ulcerative colitis: a pilot study. Inflamm Bowel Dis. 2009;15:760–768.
    1. Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–443.
    1. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3, induces remission in patients with mild-to-moderately active ulcerative colitis. Clin Gastroenterol Hepatol. 2009;7:1202–1209.
    1. Garud S, Brown A, Cheifetz A, et al. Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci. 2008;53:875–891.
    1. Ansari R, Attari F, Razjouyan H, et al. Ulcerative colitis and irritable bowel syndrome: relationships with quality of life. Eur J Gastroenterol Hepatol. 2008;20:46–50.
    1. Hanauer SB. Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. Aliment Pharmacol Ther. 2006;24 (Suppl 3:37–40.
    1. Madsen K. Probiotics in critically ill patients. J Clin Gastroenterol. 2008;42 (Suppl 3, Pt 1:S116–S118.
    1. Wallace JL, Vergnolle N, Muscará MN, et al. Enhanced anti-inflammatory effects of a nitric oxide-releasing derivative of mesalamine in rats. Gastroenterology. 1999;117:557–566.
    1. Greenfield SM, Punchard NA, Teare JP, et al. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther. 1993;7:369–383.
    1. Schlee M, Harder J, Koten B, et al. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol. 2008;151:528–535.
    1. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology. 2001;121:580–591.
    1. Caballero-Franco C, Keller K, De Simone C, et al. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol. 2007;292:G315–G322.
    1. Clayton TA, Baker D, Lindon JC, et al. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci USA. 2009;106:14728–14733.
    1. Mazmanian SK, Round JL, Kasper DL. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature. 2008;453:620–625.
    1. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313–323.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe